ARTICLE | Clinical News
GLPG0974: Completed Phase IIa enrollment
February 24, 2014 8:00 AM UTC
Galapagos completed enrollment of about 45 patients with mild to moderate UC in a double-blind, placebo-controlled, European Phase IIa trial evaluating 200 mg oral GLPG0974 twice daily for 4 weeks. ...